Biotest AG Schedules Extraordinary General Meeting at Grifols' Request

Biotest AG has announced the scheduling of an extraordinary general meeting on December 17, 2025. This decision follows a formal request from Grifols S.A. to discuss changing the company's legal structure to a partnership limited by shares (KGaA). The meeting aims to consider this reformation, with Biotest Management GmbH, a Grifols-owned entity, assuming the role of general partner. This marks the second time such a request has been made this year, with the initial notice dated October 21, 2025.

Additional agenda items from other proposals will also be addressed. These meetings are critical as Biotest continues its operations under the Grifols Group since May 2022. The company's focus remains on developing therapeutics derived from human plasma, specifically for clinical immunology and haematology. Details of the meeting have been published in the Federal Gazette and on Biotest's official website.